|
Q4 FY2026
As of Jun 30, 2026
|
Q2 FY2026
As of Jan 31, 2026
|
Q1 FY2026
As of Oct 31, 2025
|
Q4 FY2025
As of Jul 31, 2025
|
Q3 FY2025
As of Apr 30, 2025
|
Q2 FY2025
As of Jan 31, 2025
|
Q1 FY2025
As of Oct 31, 2024
|
Q4 FY2024
As of Jul 31, 2024
|
Q3 FY2024
As of Apr 30, 2024
|
Q2 FY2024
As of Jan 31, 2024
|
Q1 FY2024
As of Oct 31, 2023
|
Q4 FY2023
As of Jul 31, 2023
|
Q3 FY2023
As of Apr 30, 2023
|
|
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| ASSETS | |||||||||||||
| CURRENT ASSETS | |||||||||||||
| Cash and cash equivalents | |||||||||||||
| Inventories | |||||||||||||
| Account receivable, net | |||||||||||||
| Prepayment | |||||||||||||
| TOTAL CURRENT ASSETS | |||||||||||||
| NON-CURRENT ASSET | |||||||||||||
| Goodwill | |||||||||||||
| TOTAL NON-CURRENT ASSET | |||||||||||||
| TOTAL ASSETS | |||||||||||||
| LIABILITIES AND SHAREHOLDERS’ EQUITY | |||||||||||||
| CURRENT LIABILITIES | |||||||||||||
| Amount due to a director | |||||||||||||
| Director | |||||||||||||
| Total amount due to a director | |||||||||||||
| Other accruals | |||||||||||||
| Due to related parties | |||||||||||||
| Related Party | |||||||||||||
| Deferred revenue | |||||||||||||
| Other payables and accrued liabilities | |||||||||||||
| TOTAL CURRENT LIABILITIES | |||||||||||||
| TOTAL LIABILITIES | |||||||||||||
| SHAREHOLDERS’ EQUITY | |||||||||||||
| Common stock – Par value $ 0.001; Authorized: 75,000,000 shares; Issued and outstanding: 55,000,000 as of June 30, 2026 and March 31, 2026 | |||||||||||||
| Additional paid in capital | |||||||||||||
| Accumulated deficit | |||||||||||||
| Accumulated other comprehensive loss | |||||||||||||
| TOTAL SHAREHOLDERS’ DEFICIT | |||||||||||||
| TOTAL LIABILITIES AND SHAREHOLDERS’ DEFICIT | |||||||||||||
Loading...
